Company Overview and News
Form 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced it has appointed William Aliski to the company’s Board of Directors.
2018-09-24 247wallst - 3
Stocks have hit all-time highs, but they were indicated marginally lower on Monday after trade tariffs are set to kick in against China. Many investors have seen lower upside from buying on market pullbacks than in prior years, and now they have to consider how they want to have their investments positioned for the rest of 2018 and as 2019 approaches.
WFCNP TXRH EAT APD CCV UAA KRYS AVP DRI CCZ AMD ABT CMCSK ABT WFC AGTC RDC CMCSA NBEV UNFI UA ABRW CZR CCV.CL MU TRI COHU UNH
agtc-10k_20180630.htm UNITED STATES
Applied Genetic Technologies Corporation (NASDAQ:AGTC) Q4 2018 Results Earnings Conference Call September 10, 2018 4:30 PM ET
2018-09-10 sec.gov - 1
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the fourth quarter and fiscal year ended June 30, 2018.
2018-09-06 investorplace - 13
Forget market dynamics. These biotechs are playing to their own tune. According to the Street’s top analysts this can be a very lucrative path. Biotech stocks can spike massively on positive news — be it key trial results or regulatory approvals. Of course, the opposite is also true and the biotech sector can crash just as quickly on unexpected disappointments.
AGTC TOCA GILD OBSV SRNE GLMD MGTX NITE SBPH ABBV ALNY ABBV
2018-08-13 seekingalpha - 2
Good morning, and welcome to the Histogenics Second Quarter 2018 Financial and Operating Results Conference Call. At this time all participants are in a listen only mode. Later we’ll conduct the question-and-answer session and instructions will follow at that time. [Operator Instructions]
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President and Chief Executive Officer, will present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th, 2018 at 9:45 am ET in New York.
Form 8-K Amendment No. 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
2018-07-24 seekingalpha - 1
With multiple irons in the fire, a partnership with Biogen and topline 6-month data for its XLRS program coming in Q4, the timing appears right for a run-up.
AGTC VRTX REGN AGN
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET